Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | PTGES | O14684 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12759132 | 0.97 | EPHX1 (0.34) | SMN1; SMN2HTR2AHTR2CHTR2BPTGES | |
| SCHEMBL12759124 | 0.97 | HTR2C (0.32) | SMN1; SMN2HTR2AHTR2CHTR2B | |
| SCHEMBL12759130 | 0.97 | SMN1; SMN2 (0.35) | SMN1; SMN2HTR2AHTR2CHTR2BPTGES | |
| SCHEMBL12759119 | 0.94 | HTR2A (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL12759125 | 0.94 | EPHX1 (0.33) | SMN1; SMN2HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL12759114 | 0.92 | SLC6A2 (0.34) | HTR2AHTR2CHTR2B | |
| SCHEMBL12759128 | 0.92 | SMN1; SMN2 (0.35) | SMN1; SMN2HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL12759249 | 0.91 | SMN1; SMN2 (0.34) | SMN1; SMN2HTR2CPTGESALOX5ALDH1A1 | |
| SCHEMBL1011591 | 0.91 | EPHX1 (0.35) | HTR2AHTR2CHTR2BALDH1A1TDP1 | |
| SCHEMBL12759123 | 0.91 | HTR2C (0.33) | HTR2AHTR2CHTR2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272837-B1 | LIQUID CRYSTALLINE COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-7914862-B2 | Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7914862-B2 | Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-03-29 | — | — | US | disclosed |
| EP-2272837-A1 | LIQUID CRYSTALLINE COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | Chisso Corporation (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090278088-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090278088-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090278088-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD2, OCIAD1, CCDC22 | SMN1; SMN2 4615/4885HTR2A 1041/4885HTR2C 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.